PRIME THERAPEUTICS for PRIME THERAPEUTICS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R.10050: Pharmacist Audit & Compensation Transparency Act, a bill to require the Secretary of Health and Human Services to conduct a study on pharmacy benefit manager audit practices. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Division E Healthcare of H.R.10445, Further Continuing Appropriation and Disaster Relief Supplemental Appropriations Act of 2025: provisions regulation PBMs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Medicare/Medicaid MMM
H.R.9096: Pharmacists Fight Back Act, a bill to establish pharmacy payment and reimbursement by PBMs; to amend Medicaid and to improve prescription drug transparency. Division E Healthcare of H.R.10445, Further Continuing Appropriation and Disaster Relief Supplemental Appropriations Act of 2025: provisions regulation PBMs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.